Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Bjornsdottir E, Janson C, Lindberg E, Arnardottir ES, Benediktsdottir B, Garcia-Aymerich J, Carsin AE, Real FG, Toren K, Heinrich J, Nowak D, Sanchez-Ramos JL, Demoly P, Arenas SD, Navarro RC, Schlunssen V, Raherison C, Jarvis DL, Gislason T. Respiratory symptoms are more common among short sleepers independent of obesity. BMJ Open Respir Res. 2017 Aug 30;4(1):e000206. doi: 10.1136/bmjresp-2017-000206
Christensen T, Riis AH, Hatch EE, Wise LA, Nielsen MG, Rothman KJ, Toft Sorensen H, Mikkelsen EM. Costs and efficiency of online and offline recruitment methods: a web-based cohort study. J Med Internet Res. 2017 Mar 1;19(3):e58. doi: 10.2196/jmir.6716
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.